Literature DB >> 7745718

Assembly of the herpes simplex virus capsid: requirement for the carboxyl-terminal twenty-five amino acids of the proteins encoded by the UL26 and UL26.5 genes.

D R Thomsen1, W W Newcomb, J C Brown, F L Homa.   

Abstract

Herpes simplex virus type 1 (HSV-1) intermediate capsids are composed of seven proteins, VP5, VP19C, VP21, VP22a, VP23, VP24, and VP26, and the genes that encode these proteins, UL19, UL38, UL26, UL26.5, UL18, UL26, and UL35, respectively. The UL26 gene encodes a protease that cleaves itself and the product of the UL26.5 gene at a site (M site) 25 amino acids from the C terminus of these two proteins. In addition, the protease cleaves itself at a second site (R site) between amino acids 247 and 248. Cleavage of the UL26 protein gives rise to the capsid proteins VP21 and VP24, and cleavage of the UL26.5 protein gives rise to the capsid protein VP22a. Previously we described the production of HSV-1 capsids in insect cells by infecting the cells with recombinant baculoviruses expressing the six capsid genes (D. R. Thomsen, L. L. Roof, and F. L. Homa, J. Virol. 68:2442-2457, 1994). Using this system, we demonstrated that the products of the UL26 and/or UL26.5 genes are required as scaffolds for assembly of HSV-1 capsids. To better understand the functions of the UL26 and UL26.5 proteins in capsid assembly, we constructed baculoviruses that expressed altered UL26 and UL26.5 proteins. The ability of the altered UL26 and UL26.5 proteins to support HSV-1 capsid assembly was then tested in insect cells. Among the specific mutations tested were (i) deletion of the C-terminal 25 amino acids from the proteins coded for by the UL26 and UL26.5 genes; (ii) mutation of His-61 of the UL26 protein, an amino acid required for protease activity; and (iii) mutation of the R cleavage site of the UL26 protein. Analysis of the capsids formed with wild-type and mutant proteins supports the following conclusions: (i) the C-terminal 25 amino acids of the UL26 and UL26.5 proteins are required for capsid assembly; (ii) the protease activity associated with the UL26 protein is not required for assembly of morphologically normal capsids; and (iii) the uncleaved forms of the UL26 and UL26.5 proteins are employed in assembly of 125-nm-diameter capsids; cleavage of these proteins occurs during or subsequent to capsid assembly. Finally, we carried out in vitro experiments in which the major capsid protein VP5 was mixed with wild-type or truncated UL26.5 protein and then precipitated with a VP5-specific monoclonal antibody.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7745718      PMCID: PMC189085          DOI: 10.1128/JVI.69.6.3690-3703.1995

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  Characterization of three species of nucleocapsids of equine herpesvirus type-1 (EHV-1).

Authors:  M L Perdue; J C Cohen; M C Kemp; C C Randall; D J O'Callaghan
Journal:  Virology       Date:  1975-03       Impact factor: 3.616

2.  Use of Ar+ plasma etching to localize structural proteins in the capsid of herpes simplex virus type 1.

Authors:  W W Newcomb; J C Brown
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

3.  The products of herpes simplex virus type 1 gene UL26 which are involved in DNA packaging are strongly associated with empty but not with full capsids.

Authors:  F J Rixon; A M Cross; C Addison; V G Preston
Journal:  J Gen Virol       Date:  1988-11       Impact factor: 3.891

4.  Proteins specified by herpes simplex virus. 8. Characterization and composition of multiple capsid forms of subtypes 1 and 2.

Authors:  W Gibson; B Roizman
Journal:  J Virol       Date:  1972-11       Impact factor: 5.103

5.  Electron microscopic studies of temperature-sensitive mutants of herpes simplex virus type 1.

Authors:  P A Schaffer; J P Brunschwig; R M McCombs; M Benyesh-Melnick
Journal:  Virology       Date:  1974-12       Impact factor: 3.616

6.  Characterization of intranuclear capsids made by ts morphogenic mutants of HSV-1.

Authors:  G Sherman; S L Bachenheimer
Journal:  Virology       Date:  1988-04       Impact factor: 3.616

7.  Physical mapping and nucleotide sequence of a herpes simplex virus type 1 gene required for capsid assembly.

Authors:  B Pertuiset; M Boccara; J Cebrian; N Berthelot; S Chousterman; F Puvion-Dutilleul; J Sisman; P Sheldrick
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

8.  Structural analysis of the capsid polypeptides of herpes simplex virus types 1 and 2.

Authors:  G H Cohen; M Ponce de Leon; H Diggelmann; W C Lawrence; S K Vernon; R J Eisenberg
Journal:  J Virol       Date:  1980-05       Impact factor: 5.103

9.  Antigenic variants of herpes simplex virus selected with glycoprotein-specific monoclonal antibodies.

Authors:  T C Holland; S D Marlin; M Levine; J Glorioso
Journal:  J Virol       Date:  1983-02       Impact factor: 5.103

Review 10.  The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1.

Authors:  D J McGeoch; M A Dalrymple; A J Davison; A Dolan; M C Frame; D McNab; L J Perry; J E Scott; P Taylor
Journal:  J Gen Virol       Date:  1988-07       Impact factor: 3.891

View more
  52 in total

1.  Roles of triplex and scaffolding proteins in herpes simplex virus type 1 capsid formation suggested by structures of recombinant particles.

Authors:  A Saad; Z H Zhou; J Jakana; W Chiu; F J Rixon
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

2.  The kinetics of VP5 mRNA expression is not critical for viral replication in cultured cells.

Authors:  P T Lieu; E K Wagner
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

3.  ATP-Dependent localization of the herpes simplex virus capsid protein VP26 to sites of procapsid maturation.

Authors:  J H Chi; D W Wilson
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

4.  Lytic replication of Kaposi's sarcoma-associated herpesvirus results in the formation of multiple capsid species: isolation and molecular characterization of A, B, and C capsids from a gammaherpesvirus.

Authors:  K Nealon; W W Newcomb; T R Pray; C S Craik; J C Brown; D H Kedes
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

5.  Cytomegalovirus capsid protease: biological substrates are cleaved more efficiently by full-length enzyme (pUL80a) than by the catalytic domain (assemblin).

Authors:  Steve M Fernandes; Edward J Brignole; Kanchan Taori; Wade Gibson
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

6.  pH reduction as a trigger for dissociation of herpes simplex virus type 1 scaffolds.

Authors:  David A McClelland; James D Aitken; David Bhella; David McNab; Joyce Mitchell; Sharon M Kelly; Nicholas C Price; Frazer J Rixon
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

7.  Mutation of single hydrophobic residue I27, L35, F39, L58, L65, L67, or L71 in the N terminus of VP5 abolishes interaction with the scaffold protein and prevents closure of herpes simplex virus type 1 capsid shells.

Authors:  Jewell N Walters; Gerry L Sexton; J Michael McCaffery; Prashant Desai
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

8.  Identification of a region in the herpes simplex virus scaffolding protein required for interaction with the portal.

Authors:  Gregory P Singer; William W Newcomb; Darrel R Thomsen; Fred L Homa; Jay C Brown
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

9.  Cleavage of human cytomegalovirus protease pUL80a at internal and cryptic sites is not essential but enhances infectivity.

Authors:  Amy N Loveland; Chee-Kai Chan; Edward J Brignole; Wade Gibson
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

10.  The bovine herpesvirus 1 maturational proteinase and scaffold proteins can substitute for the homologous herpes simplex virus type 1 proteins in the formation of hybrid type B capsids.

Authors:  E J Haanes; D R Thomsen; S Martin; F L Homa; D E Lowery
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.